About vedolizuma b + vial
Gut-selective integrin antagonist
Used for
- Moderate to severe ulcerative colitis
- Moderate to severe Crohn’s disease
Usual adult dose
300 mg by intravenous infusion at weeks 0, 2, and 6, then every 8 weeks.
Common side effects
- Headache
- Joint pain
- Nausea
- Infusion reactions
Important warnings
- Serious infections can occur; assess for infection before treatment.
- Screen for tuberculosis before starting treatment.
- Rare progressive multifocal leukoencephalopathy has been reported.
- Monitor for allergic reactions during and after infusions.
Pregnancy
Human pregnancy data are limited. Use only when the expected benefit justifies potential risk.
Breastfeeding
Vedolizumab may enter breast milk; effects on nursing infants are uncertain.
Interactions
- Avoid live vaccines during treatment.
- Other biologic medicines or immunosuppressants may increase infection risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.